DERMATA THERAPEUTICS INC

Gerald Proehl’s massive buy‑in of Dermata Therapeutics shares shows insider confidence but raises dilution worries for investors watching the new private placement and warrant activity.

Dermata insiders’ option purchases signal confidence, but the next earnings report will decide if the biotech’s stock can rally beyond its current volatility.